logo
logo

Alumis Inc. raised $259M in a upsized funding round to support its clinical-stage biopharmaceutical development.

Alumis Inc. raised $259M in a upsized funding round to support its clinical-stage biopharmaceutical development.

03/07/24, 5:32 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgsan francisco
Money raised
$259 million
Industry
biotechnology
health care
Round Type
series c
Investors
Venture Capital Investors
South San Francisco-based clinical-stage biopharmaceutical company Alumis Inc. closed its upsized Series C funding round after securing $259 million from venture capital investors.

Company Info

Company
Alumis
Location
san francisco, california, united states
Additional Info
A California-based biotech company specializing in developing oral therapies for immune dysfunction and autoimmune indications, with a focus on TYK2 inhibition.

Related People